ERG and prostate cancer: We recently reported that YK-4-279, an inhibitor of EWS-FLI1 oncoprotein in Ewings sarcoma, also inhibits ERG and ETV1 activity in prostate cancer cells in-vitro, resulting in reduced migratory and invasive phenotypes [12], [13].